Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 2—February 2006
Perspective

Antimicrobial Drug Resistance, Regulation, and Research1

Joshua P. Metlay*†Comments to Author , John H. Powers‡, Michael N. Dudley§, Keryn Christiansen¶, Roger G. Finch#**, on behalf of the Second Colloquium of the International Forum on Antibiotic Resistance
Author affiliations: *VA Medical Center, Philadelphia, Pennsylvania, USA; †University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; ‡US Food and Drug Administration, Rockville, Maryland, USA; §Diversa Corporation, San Diego, California, USA; ¶Royal Perth Hospital, Perth, Western Australia, Australia; #Nottingham City Hospital, Nottingham, United Kingdom; **University of Nottingham, Nottingham, United Kingdom

Main Article

Figure 3

Relationship between MIC and attainment of the pharmacokinetic/pharmacodynamic (PK/PD) target for effect. Accumulating evidence supports the use of separate PK/PD breakpoints for clinical decision making, distinct from in vitro breakpoints used for epidemiologic surveillance. A breakpoint derived from PK/PD data represents the highest MIC for which the unbound plasma concentrations of the drug (after standard doses) are sufficient to achieve the target PK/PD exposure.

Figure 3. Relationship between MIC and attainment of the pharmacokinetic/pharmacodynamic (PK/PD) target for effect. Accumulating evidence supports the use of separate PK/PD breakpoints for clinical decision making, distinct from in vitro breakpoints used for epidemiologic surveillance. A breakpoint derived from PK/PD data represents the highest MIC for which the unbound plasma concentrations of the drug (after standard doses) are sufficient to achieve the target PK/PD exposure.

Main Article

1This article is based on presentations and discussions held at the Second Colloquium of the International Forum on Antibiotic Resistance (IFAR), held on September 13, 2003, in Chicago, Illinois, USA. IFAR is a multidisciplinary, international group concerned with evaluating current knowledge regarding antimicrobial drug resistance and the means for its control. This article represents the opinions of the participants at the second IFAR colloquium and not necessarily those of the institutions for whom they work.

Page created: February 02, 2012
Page updated: February 02, 2012
Page reviewed: February 02, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external